1289 genes changed with higher doses of Vitamin D - RCT
Disassociation of Vitamin D's Calcemic Activity and non-calcemic Genomic Activity and Individual Responsiveness: A Randomized controlled Double-Blind clinical Trial
Scientific RepoRtS | (2019) 9:17685 | https://doi.org/10.1038/s41598-019-53864-1
Arash Shirvani ,tyler Arek Kalajian, Anjeli Song & Michael F. Holick*
Graphic and web page in GermanTitle translated from German: Vitamin D commands over 1200 genes - but only at a vitamin D level of 78 ng / mlGraphics by GRH: 8X more genes changed
--- 1. Vitamin D ReceptorVitamin D Receptor category has the following{include}10+ Vitamin D Receptor studies have overlaps to Health Problems* VDR & Diabetes studies* VDR & Breathing studies* VDR & Breast Cancer studies* VDR & Cancer - general studies* VDR & Obesity studies* VDR &Multiple; Sclerosis studies--- 1. Vitamin D Binding ProteinMS and Vitamin D Binding Protein: {category}TB and Vitamin D Binding Protein: {category}Breathing and Vitamin D Binding Protein: {category}Infant-Child and Vitamin D Binding Protein: {category}Pregnancy and Vitamin D Binding Protein: {category}📄 Download the PDF from Vitamin D Life
The aims of this randomized controlled double-blind clinical trial were to assess the impact of vitamin D supplementation on calcium metabolism and non-calcemic broad gene expression by relating them to the individual's responsiveness to varying doses of vitamin D3. thirty healthy adults were randomized to receive 600, 4,000 or 10,000 IU/d of vitamin D3 for 6 months. Circulating parathyroid hormone (PTH), 25(OH)D, calcium and peripheral white blood cells broad gene expression were evaluated. We observed a dose-dependent increase in 25(OH)D concentrations, decreased PTH and no change in serum calcium. A plateau in PTH levels was achieved at 16 weeks in the 4000 and 10,000 IU/d groups. There was a dose-dependent 25(OH)D alteration in broad gene expression with 162, 320 and 1289 genes up- or down-regulated in their white blood cells, respectively. our results clearly indicated that there is an individual's responsiveness on broad gene expression to varying doses of vitamin D3. Vitamin D3 supplementation at 10,000 IU/d produced genomic alterations several fold higher than 4,000 IU/d even without further changes in PTH levels. Our findings may help explain why there are some inconsistency in the results of different vitamin D's clinical trials.
Title change made July 2022 caused the visitor count to reset.
There have actually been visitors to this page since it was originally made